Matrix Overlay Cardiomyocyte Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating pluripotent stem cells into cardiomyocytes are inefficient and lack broad applicability across multiple cell lines, relying on soluble growth factors without considering the role of the extracellular matrix in promoting initial differentiation steps.
Innovation Solution
Culturing pluripotent stem cells in feeder-free, defined medium with a matrix overlay, such as MATRIGEL®, and applying growth factors like Activin A, BMP4, and bFGF to induce epithelial-to-mesenchymal transition and direct cardiomyocyte differentiation, eliminating the need for embryoid body formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If embryoid body formation is used for cardiac differentiation, then cardiomyocytes can be generated, but the efficiency is low with only a few percent of cells becoming cardiomyocytes
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the concentrations and combinations of soluble factors (Activin A, BMP4, bFGF, VEGF, DKK1) to transform the inefficient spontaneous differentiation process into a highly efficient directed differentiation protocol that generates 70-90% cardiomyocytes
Solution Approach 2:
The patent uses soluble growth factors and small molecules as intermediaries to mediate and direct the differentiation process, replacing the inefficient embryoid body formation with a controlled chemical signaling approach that guides stem cells through specific developmental pathways
2Productivity
If soluble growth factors are applied sequentially to mimic cardiac development, then cardiomyocyte differentiation is promoted, but the method lacks broad applicability across multiple stem cell lines
Solution Approach 1:
The patent achieves universality by developing a standardized differentiation protocol using defined soluble factors that successfully generates cardiomyocytes from multiple human embryonic stem cell lines and induced pluripotent stem cell lines, making the method broadly applicable across different stem cell sources
Solution Approach 2:
The patent uses parameter changes by optimizing the concentrations, timing, and combinations of growth factors to create a robust protocol that works across different stem cell lines, transforming a line-specific approach into a universal method
3Productivity
If retroviral vectors are used to generate iPS cells, then pluripotent stem cells can be produced, but exogenous DNA integration causes aberrant gene expression and neoplastic growth
Solution Approach 1:
The patent applies the taking out principle by removing the harmful retroviral integration step from the iPS cell generation process, using alternative non-integrating methods to reprogram somatic cells while maintaining their ability to differentiate into cardiomyocytes through the soluble factor protocol
Data Source
AI summary
Methods for culturing the pluripotent stem cells to undergo epithelial-to-mesenchymal transition and for generating high-yield, high-purity cardiomyocyte cultures from pluripotent stem cells are described. Pluripotent stem cells are cultured on a support with an overlaid matrix and, optionally, exposed to one or more factors to induce epithelial-to-mesenchymal transition and cardiogenesis.